Plain-English translation of NCT00576069 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →This trial is studying people with moderate-to-severe asthma to understand exactly why their airways become blocked and how their lungs respond to treatment. You would take one of three combination inhalers (Advair, Symbicort, or Dulera) along with another daily inhaler called tiotropium, plus a rescue inhaler for flare-ups. Researchers will measure your lung function and how the treatment affects your quality of life.
Many people with moderate-to-severe asthma continue to have breathing problems even when treated with standard medications. Doctors want to understand the specific reasons why this happens in different patients so they can develop better treatments.
You likely qualify if…
You likely don't qualify if…
You would be started on one of the three combination inhalers along with the additional daily inhaler, and researchers would measure your lung function and assess your asthma symptoms and quality of life over time. The study evaluates you both when your asthma is stable and if you experience a flare-up, so doctors can see how the medication works in different situations. You would also complete a questionnaire about how your asthma affects your daily life.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Enrollment target
~60 participants
Started
October 2007
Primary completion
June 2027
Age range
10 Years – 95 Years
Last updated on clinicaltrials.gov in October 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Arthur F Gelb, MD
Arthur F Gelb Medical Corporation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.